MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561642 | Name: Pamoic acid
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pamoic acid is an agonist of the orphan G protein-coupled receptor GPR35. It activates ERK and beta-arrestin2 and causes antinociceptive activity.

Chemical Structure

Pamoic acid
Pamoic acid
CAS#130-85-8

Theoretical Analysis

MedKoo Cat#: 561642

Name: Pamoic acid

CAS#: 130-85-8

Chemical Formula: C23H16O6

Exact Mass: 388.0947

Molecular Weight: 388.38

Elemental Analysis: C, 71.13; H, 4.15; O, 24.72

Price and Availability

Size Price Availability Quantity
50g USD 250.00 2 weeks
100g USD 450.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Pamoic acid; Embonic acid; NSC-30188; NSC 30188; NSC30188;
IUPAC/Chemical Name
4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)
InChi Key
WLJNZVDCPSBLRP-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H16O6/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h1-10,24-25H,11H2,(H,26,27)(H,28,29)
SMILES Code
O=C(O)C1=C(O)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C4C=CC=CC4=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Pamoic acid is a potent GPR35 agonist with an EC50 of 79 nM.
In vitro activity:
To confirm that pamoic acid also activates GPR35 from other species, HEK293 cells were transiently cotransfected with plasmids for untagged mouse GPR35 and βarr2-GFP. Application of either pamoic acid (1 μM) or zaprinast (5 μM) induced trafficking of βarr2-GFP (Supplemental Fig. S5) was prevented by coincubation with CID2745687. Reference: Mol Pharmacol. 2010 Oct;78(4):560-8. https://pubmed.ncbi.nlm.nih.gov/20826425/
In vivo activity:
This study shows in a mouse model of stroke that GPR35 activation by pamoic acid is neuroprotective. Pharmacological inhibition of GPR35 reveals that pamoic acid reduces infarcts size in a GPR35 dependent manner. The flowcytometric analysis shows the expression of GPR35 on the infiltrating monocytes/macrophages and neutrophils in the ischemic brain. Pamoic acid treatment results in a preferential increment of noninflammatory Ly-6CLo monocytes/macrophages in the ischemic brain along with the reduced neutrophil counts. Reference: Sci Rep. 2020 Jun 10;10(1):9400. https://pubmed.ncbi.nlm.nih.gov/32523084/
Solvent mg/mL mM comments
Solubility
DMSO 25.1 87.04
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 388.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TD, Bai Y, Chen W, Caron MG, Barak LS, Abood ME. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8. doi: 10.1124/mol.110.066746. Epub 2010 Jul 22. PMID: 20826425; PMCID: PMC2981393. 2. De Leo F, Rossi A, De Marchis F, Cigana C, Melessike M, Quilici G, De Fino I, Mantonico MV, Fabris C, Bragonzi A, Bianchi ME, Musco G. Pamoic acid is an inhibitor of HMGB1·CXCL12 elicited chemotaxis and reduces inflammation in murine models of Pseudomonas aeruginosa pneumonia. Mol Med. 2022 Sep 7;28(1):108. doi: 10.1186/s10020-022-00535-z. PMID: 36071400; PMCID: PMC9449960. 3. Sharmin O, Abir AH, Potol A, Alam M, Banik J, Rahman AFMT, Tarannum N, Wadud R, Habib ZF, Rahman M. Activation of GPR35 protects against cerebral ischemia by recruiting monocyte-derived macrophages. Sci Rep. 2020 Jun 10;10(1):9400. doi: 10.1038/s41598-020-66417-8. PMID: 32523084; PMCID: PMC7287103.
In vitro protocol:
1. Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TD, Bai Y, Chen W, Caron MG, Barak LS, Abood ME. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8. doi: 10.1124/mol.110.066746. Epub 2010 Jul 22. PMID: 20826425; PMCID: PMC2981393.
In vivo protocol:
1. De Leo F, Rossi A, De Marchis F, Cigana C, Melessike M, Quilici G, De Fino I, Mantonico MV, Fabris C, Bragonzi A, Bianchi ME, Musco G. Pamoic acid is an inhibitor of HMGB1·CXCL12 elicited chemotaxis and reduces inflammation in murine models of Pseudomonas aeruginosa pneumonia. Mol Med. 2022 Sep 7;28(1):108. doi: 10.1186/s10020-022-00535-z. PMID: 36071400; PMCID: PMC9449960. 2. Sharmin O, Abir AH, Potol A, Alam M, Banik J, Rahman AFMT, Tarannum N, Wadud R, Habib ZF, Rahman M. Activation of GPR35 protects against cerebral ischemia by recruiting monocyte-derived macrophages. Sci Rep. 2020 Jun 10;10(1):9400. doi: 10.1038/s41598-020-66417-8. PMID: 32523084; PMCID: PMC7287103.
1: Park EJ, Amatya S, Kim MS, Park JH, Seol E, Lee H, Shin YH, Na DH. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res. 2013 Jun;36(6):651-9. doi: 10.1007/s12272-013-0105-7. Epub 2013 Apr 1. Review. PubMed PMID: 23543652. 2: Anderson G, Maes M, Berk M. Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization. Adv Protein Chem Struct Biol. 2012;88:27-48. doi: 10.1016/B978-0-12-398314-5.00002-7. Review. PubMed PMID: 22814705. 3: Neubig RR. Mind your salts: when the inactive constituent isn't. Mol Pharmacol. 2010 Oct;78(4):558-9. doi: 10.1124/mol.110.067645. Epub 2010 Jul 22. Review. PubMed PMID: 20651116. 4: De Saint-Hubert M, Prinsen K, Mortelmans L, Verbruggen A, Mottaghy FM. Molecular imaging of cell death. Methods. 2009 Jun;48(2):178-87. doi: 10.1016/j.ymeth.2009.03.022. Epub 2009 Apr 9. Review. PubMed PMID: 19362149.